Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Phase
3Span
219 weeksSponsor
Merck Sharp & Dohme LLCUshiku, Ibaraki
Recruiting
1-1 of 1